A Pharmacy's Complete Guide to DMEPOS Accreditation Requirements in 2025

Recent Trends

Throughout 2024 and into 2025, accreditation requirements for pharmacies billing Medicare as Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) suppliers have continued to tighten. Industry observers note a renewed emphasis on retroactive documentation audits, beneficiary-facing compliance, and the integration of digital recordkeeping into daily pharmacy workflows. Many pharmacies that previously relied on third-party billing arrangements are now revisiting their direct supplier status to ensure they meet current standards before re-enrollment deadlines.

A second visible trend is the shift toward consolidated accreditation standards. The two dominant accrediting bodies remain in widespread use, yet their survey processes increasingly mirror one another in areas such as inventory control, non-physician order review, and face-to-face documentation. Pharmacies that historically prepared for one surveyor's style should expect less variance in 2025, making cross-accreditation preparation more efficient but also more demanding on consistent daily operations.

Background

DMEPOS accreditation is a mandatory condition for pharmacies that want to bill Medicare for certain medical equipment and supplies. The requirement stems from the Medicare Modernization Act and has been enforced through the Centers for Medicare & Medicaid Services (CMS) supplier standards since the late 2000s. While many pharmacies focus on traditional prescription dispensing, any location that rents or sells oxygen equipment, hospital beds, walkers, or diabetic testing supplies under a Medicare Part B benefit must maintain active accreditation from a CMS-approved organization.

For pharmacies, the practical scope of compliance generally spans four areas:

• Supplier standards, including physical location accessibility and hours of operation
• Staff training and competency documentation for equipment education
• Order and proof-of-delivery documentation, especially for face-to-face requirements
• Complaint handling, return policies, and beneficiary protections

Renewal cycles typically occur every three years, though a reopening or a change in pharmacy ownership can trigger an earlier full survey. Pharmacies that bill for only a narrow set of items, such as diabetic supplies alone, still face the same accreditation burden as those offering complex rehab equipment, because CMS does not apply a partial-supplier designation.

User Concerns

Pharmacies most often raise the same practical concerns when approaching a 2025 accreditation survey. The first is documentation of the face-to-face encounter. CMS rules require that a physician or certain non-physician practitioners see the beneficiary within a defined timeframe before the order is written, and pharmacies must retain evidence of that encounter. In practice, many pharmacies find that referring physicians are unfamiliar with the requirement, leaving the pharmacy to chase missing records shortly before an audit.

A second concern is the accreditation survey timeline itself. Pharmacies frequently underestimate how far in advance they must apply for a renewal. Surveyors commonly fill windows several months out, and CMS requires continuous accreditation without a lapse. If a pharmacy allows its current accreditation to expire during the approval gap, it loses billing privileges and must re-enroll from scratch, a process that can disrupt cash flow for a significant period.

Inventory control also creates anxiety, particularly for pharmacies that do not maintain dedicated DMEPOS stock. The accrediting bodies expect traceability from purchase to billing to delivery, including lot numbers when applicable. Pharmacies that treat DME like ordinary retail inventory often face the highest number of findings during the survey.

Likely Impact

For 2025, the most likely impact on pharmacies is an increase in preparation lead time and administrative overhead. Practices that previously survived on lightweight documentation will need to formalize their workflows around receive, verify, deliver, and bill. This may push some smaller pharmacies to partner with or sell to larger organizations that already maintain compliance infrastructure, especially in competitive urban markets where reimbursement margins are thin.

Another expected impact is the growing role of delegated credentialing and billing intermediaries. Pharmacies that use outside billing agencies should expect those vendors to demand stronger evidence of internal compliance before submitting claims. Vendors, in turn, may drop pharmacies that cannot produce clean documentation on request, since a single poor-performing supplier can trigger a broader CMS review of the billing company's portfolio.

The shift toward more routine, unannounced post-accreditation audits also appears likely as CMS continues to rely on data analytics to flag anomaly patterns. A pharmacy that passes its initial survey is not shielded from later document requests, meaning compliance must be maintained continuously rather than only during survey season.

What to Watch Next

Pharmacies should monitor CMS updates to the DMEPOS supplier standards throughout the year, as the agency occasionally revises interpretive guidance without major public rulemaking. Changes to the list of products that require accreditation are another area to track, particularly as new remote patient monitoring devices and digital therapeutics enter the Medicare benefit.

Finally, watch for policy movement on accreditation fee transparency and surveyor consistency. Pharmacy trade groups have called for clearer cost disclosures from accrediting organizations, and any legislative or administrative response could alter renewal budgets. For most pharmacies, the safest near-term action is to run an internal gap analysis against the current CMS supplier standards, review the accreditation renewal date, and begin compiling face-to-face encounter documentation at the point of sale rather than after the fact.